Three representative primary endometrial cancer cell lines (two TROP2 3+ and one TROP2 non-expressing) were tested for their sensitivity to ADCC when challenged with heterologous PBMCs from healthy donors in standard 4-hour 51Cr release assays. This evidence concerns the gene TACSTD2 and endometrial cancer.